The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines

Oncotarget

Volumn 7, Issue 38, 2016, Pages 61021-61035

  Carino, Adriana ^a   Graziosi, Luigina ^b   D'Amore, Claudio ^a   Cipriani, Sabrina ^a   Marchianò, Silvia ^a   Marino, Elisabetta ^b   Zampella, Angela ^c   Rende, Mario ^a   Mosci, Paolo ^a   Distrutti, Eleonora ^b   Donini, Annibale ^a   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bile acids; Epithelial mesenchymal transition; Gastric cancer; TGR5

Indexed keywords

CETUXIMAB; COLLAGENASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPBAR1 PROTEIN; HERMES ANTIGEN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE CELL ADHESION MOLECULE; OLEANOLIC ACID; STROMELYSIN 2; UNCLASSIFIED DRUG; CADHERIN; CD44 PROTEIN, HUMAN; CDH2 PROTEIN, HUMAN; CHENODEOXYCHOLIC ACID; GPBAR1 PROTEIN, HUMAN; HYALURONIC ACID BINDING PROTEIN; LEUKOCYTE ANTIGEN; OBETICHOLIC ACID;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FAT1 GENE; FEMALE; GASTRIC CANCER CELL LINE; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; IGB3 GENE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KDKN2A GENE; MALE; ONCOGENE H RAS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR VOLUME; WOUND HEALING; ANALOGS AND DERIVATIVES; ANIMAL; CANCER TRANSPLANTATION; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; GENETICS; HEP-G2 CELL LINE; METABOLISM; MIDDLE AGED; MOUSE; NONOBESE DIABETIC MOUSE; PERITONEUM; SCID MOUSE; STOMACH TUMOR; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD; CADHERINS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHENODEOXYCHOLIC ACID; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; HYALURONAN RECEPTORS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION; OLEANOLIC ACID; PERITONEUM; RECEPTORS, G-PROTEIN-COUPLED; STOMACH NEOPLASMS; WOUND HEALING;

EID: 84992530540     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10477     Document Type: Article

References (37)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, and Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012; Int J Cancer. 2015. 136:e359-e386.
2. Qiu MZ, Xu RH. The progress of targeted therapy in advanced gastric cancer. Biomark Res. 2013; 1:32-40.
3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, and Norman AR. Upper gastrointestinal clinical studies group of the national cancer research institute of the United Kingdom: capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358:36-46.
4. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res. 2009; 50:1955-1966.
5. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, and Kliewer SA. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000; 6:517-526.
6. Saini SP, Sonoda J, Xu L, Toma D, Uppal H, Mu Y, Ren S, Moore DD, Evans RM, and Xie W. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol Pharmacol. 2004; 65:292-300.
7. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, and Kliewer SA. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A. 2001; 98: 3369-3374.
8. Song C, Hiipakka RA, and Liao S. Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs. Steroids. 2000 ; 65:423-427.
9. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, and Mangelsdorf DJ. Vitamin D receptor as an intestinal bile acid sensor. Science. 2002; 296:1313-1316.
10. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, and Fujino M. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003; 278: 9435-9440.
11. Katsuma S Hirasawa A, and Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005; 329: 386-390.
12. Fiorucci S, Mencarelli A, Palladino G, and Cipriani S. Bileacid activated receptors: targeting TGR5 and farnesoid X receptor in lipid and glucose disorders. Trends Pharmacol Sci. 2009; 30:570-580.
13. Fiorucci S, Distrutti E. Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders. Trends Mol Med. 2015; 21:702-14.
14. Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, Baldelli F, Donini A, and Fiorucci S. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One. 2011; 6:e25637.
15. Dixon MF, Mapstone NP, Neville PM, Moayyedi P, and Axon AT. Bile reflux gastritis and intestinal metaplasia at the cardia. Gut. 2002; 51:351-355.
16. Kondo K. Duodenogastric reflux and gastric stump carcinoma. Gastric Cancer. 2002; 5:16-22.
17. Miwa K, Hasegawa H, Fujimura T, Matsumoto H, Miyata R, Kosaka T, Miyazaki I, and Hattori T. Duodenal reflux through the pylorus induces gastric adenocarcinoma in the rat. Carcinogenesis. 1992; 13: 2313-2316.
18. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, and Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002; 122:985-993.
19. Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H, and Yoshiba M. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun. 2007; 354:154-159.
20. Cao W, Tian W, Hong J, Li D, Tavares R, Noble L, Moss SF, and Resnick MB. Expression of bile acid receptor TGR5 in gastric adenocarcinoma. Am J Physiol Gastrointest Liver Physiol. 2013; 304:g322-327.
21. Hong J, Behar J, Wands J, Resnick M, Wang LJ, DeLellis RA, Lambeth D, Souza RF, Spechler SJ, and Cao W. Role of a novel bile acid receptor TGR5 in the development of esophageal adenocarcinoma. Gut. 2010; 59:170-180.
22. Casaburi I, Avena P, Lanzino M, Sisci D, Giordano F, Maris P, Catalano S, Morelli C, and Andò S. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle. 2012; 11:2699-2710.
23. Guo C, Su J, Li Z, Xiao R, Wen J, Li Y, Zhang M, Zhang X, Yu D, Huang W, Chen WD, and Wang YD. The G-proteincoupled bile acid receptor Gpbar1 (TGR5) suppresses gastric cancer cell proliferation and migration through antagonizing STAT3 signaling pathway. Oncotarget. 2015; 6:34402-34413. doi: 10.18632/oncotarget.5353.
24. Kim MA, Lee HS, Lee HE, Kim JH, Yang HK, and Kim WH. Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma. Histopathology. 2009; 54: 442-451.
25. Ye X, Weinberg RA. Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends Cell Biol. 2015; 25:675-686.
26. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010; 17:3077-9.
27. Lauren P. THE two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965; 64: 31-49.
28. Sepe V, Renga B, Festa C, Finamore C, Masullo D, Carino A, Cipriani S, Distrutti E, Fiorucci S, and Zampella A. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity. Steroids. 2016; 105:59-67.
29. Rodriguez LG, Wu X, and Guan JL. Wound-healing assay. Methods Mol Biol. 2005; 294:23-29.
30. Mencarelli A, Graziosi L, Renga B, Cipriani S, D'Amore C, Francisci D, Bruno A, Baldelli F, Donini A, and Fiorucci S. CCR5 antagonism by maraviroc reduces the potential for gastric cancer cell dissemination. Transl Oncol. 2013; 6:784-93.
31. Nagathihalli NS, Beesetty Y, Lee W, Washington MK, Chen X, Lockhart AC, and Merchant NB. Novel mechanistic insights into ectodomain shedding of EGFR Ligands amphiregulin and TGF-a: impact on gastrointestinal cancers driven by secondary bile acids. Cancer Res. 2014; 74:2062-2072.
32. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011; 10:47-60.
33. Sampieri CL, León-Córdoba K, and Remes-Troche JM. Matrix metalloproteinases and their tissue inhibitors in gastric cancer as molecular markers. J Cancer Res Ther. 2013; 9:356-363.
34. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, et al. An integrin β3-KRASRalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014; 16:457-468.
35. Desgrosellier JS & Cheresh DA. Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer. 2010; 10:9-22.
36. Aoyagi K, Kouhuji K, Kizaki J, Isobe T, Hashimoto K, and Shirouzu K. Molecular targeting to treat gastric cancer. World J Gastroenterol. 2014; 20:13741-13755.
37. Okines A, Cunningham D, and Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol. 2011; 8:492-503.